CJC-1295 DAC 5mg is a synthetic 29-amino-acid growth-hormone-releasing hormone (GHRH) analog modified with a Drug Affinity Complex (DAC). Designed for an extended half-life in laboratory models, this research compound allows investigators to analyze sustained GH secretion and downstream IGF-1 dynamics in cell culture and animal models of tissue repair.
CJC-1295 DAC 5mg is a synthetic 29-amino-acid growth-hormone-releasing hormone (GHRH) analog modified with a Drug Affinity Complex (DAC). Designed for an extended half-life in laboratory models, this research compound allows investigators to analyze sustained GH secretion and downstream IGF-1 dynamics in cell culture and animal models of tissue repair.
CJC-1295 DAC 5mg represents a modified, truncated functional analog of endogenous growth-hormone-releasing hormone (GHRH 1-29). The inclusion of the Drug Affinity Complex (DAC)—specifically a reactive maleimide derivative of 3-maleimidopropionic acid linked to the C-terminus lysine residue—dramatically alters the pharmacokinetic profile of the native peptide sequence. When introduced to biological media or serum, the maleimide group forms a covalent bioconjugate bond with circulating albumin, utilizing endogenous albumin as a natural carrier protein.
In laboratory research settings, this covalent conjugation shields the peptide core from rapid proteolytic cleavage by dipeptidyl peptidase-IV (DPP-IV) and renal filtration. As a result, researchers utilize the CJC-1295 DAC 5mg format to study baseline GHRH receptor signaling across prolonged experimental windows without needing perpetual re-administration in preclinical subjects.
The primary mechanism of CJC-1295 DAC centers on its selective interaction with the growth-hormone-releasing hormone receptor (GHRH-R), a G-protein coupled receptor situated on anterior pituitary somatotrophs. Upon receptor binding, the compound stimulates the intracellular adenylate cyclase system, elevating cyclic adenosine monophosphate (cAMP) levels and triggering protein kinase A (PKA) signaling cascades. This pathway prompts both the synthesis and exocytosis of growth hormone (GH).
Unlike short-acting secretagogues, the persistent circulating concentration of CJC-1295 DAC alters standard secretory dynamics. Preclinical evaluations demonstrate that continuous receptor occupancy produces sustained elevations in baseline GH release. Detailed analysis of receptor signaling pathways can be explored further within the research library hub.
A critical outcome of GHRH receptor activation is the hepatic generation and systemic distribution of Insulin-like Growth Factor 1 (IGF-1). In rodent models, sustained GHRH agonism driven by CJC-1295 DAC results in dose-dependent increases in serum IGF-1 concentration. Because IGF-1 serves as a primary mediator of cellular proliferation, differentiation, and protein synthesis, researchers frequently monitor IGF-1 expression as a secondary biomarker of GHRH activation.
Literature indicates that elevated IGF-1 levels downstream of continuous GHRH-R stimulation stimulate skeletal muscle satellite cell activation, chondrocyte extracellular matrix synthesis, and fibroblast collagen deposition. Studies examining these tissue remodeling pathways often source high-purity research peptides to ensure reliable analytical baselines.
When designing comparative secretagogue protocols, researchers must evaluate differences between extended-release analogs and short-acting pulse generators. CJC-1295 DAC provides a continuous baseline elevation of GH, whereas CJC-1295 No DAC (Mod GRF 1-29) exhibits a short plasma half-life (~30 minutes) requiring targeted sampling windows to capture acute GH spikes. Similarly, first-generation analogs like Sermorelin mimic native short-lived GHRH pulses.
To achieve synergistic GH release in vitro or in vivo models, investigators frequently pair GHRH analogs with growth hormone secretagogue receptor (GHSR-1a) agonists. For instance, combining GHRH pathway agonism with a ghrelin mimetic like Ipamorelin amplifies total pituitary GH release via dual, non-competing receptor mechanisms. Additional comparative literature on secretagogue families is available in our GHRH research overview.
Preclinical investigations focusing on tissue repair utilize CJC-1295 DAC to evaluate acceleration rates in musculoskeletal healing, wound closure, and nitrogen retention. In animal models of skeletal injury, sustained IGF-1 activity upregulated by CJC-1295 DAC facilitates satellite cell recruitment to damaged myofibers, promoting hypertrophy and accelerating structural restoration.
Furthermore, metabolic research assays examine how prolonged baseline GH elevations alter lipid metabolism and glucose homeostasis. GH exhibits potent lipolytic activity via hormone-sensitive lipase activation in adipose tissue. Preclinical data indicate that continuous exposure to CJC-1295 DAC enhances free fatty acid oxidation while maintaining lean tissue mass in animal models of metabolic stress.
Proper handling and reconstitution of lyophilized CJC-1295 DAC 5mg are essential to maintain peptide integrity and prevent aggregation. Research facilities should adhere to standardized sterile handling procedures within a laminar flow hood:
1. Allow the lyophilized 5mg CJC-1295 DAC vial to equilibrate to room temperature prior to reconstitution to minimize moisture condensation upon opening. 2. Clean the rubber stopper using a 70% isopropyl alcohol wipe and allow it to air-dry completely. 3. Using a sterile syringe, slowly introduce bacteriostatic water (0.9% benzyl alcohol preserved) or sterile deionized water down the glass wall of the vial. Avoid spraying diluent directly onto the lyophilized cake. 4. Gently swirl the vial in a circular motion until the cake dissolves completely. Never shake or agitate the vial, as mechanical shear stress can disrupt the peptide's secondary structure. 5. Inspect the solution visually. Reconstituted CJC-1295 DAC must appear clear, colorless, and free of visible particulate matter prior to pipette transfer.
Lyophilized CJC-1295 DAC 5mg is stable when stored at -20°C in a desiccated environment, shielded from light exposure. Under these conditions, the dry powder preserves chemical stability for up to 24 months from the date of synthesis. Exposure to elevated temperatures or ambient humidity accelerates hydrolytic and oxidative degradation pathways.
Once reconstituted with bacteriostatic diluent, the liquid solution must be stored at 2°C to 8°C and evaluated within a 30-day window. Repeated freeze-thaw cycles must be avoided entirely, as physical phase changes induce aggregation and loss of bioactive mass. For long-term liquid storage, aliquoting into sterile microcentrifuge tubes prior to initial freezing is recommended.
To ensure reproducible assay outcomes, research compounds must strictly match documented purity specifications. Every lot of CJC-1295 DAC 5mg supplied by PX1 Research undergoes rigorous analytical testing at ISO 17025 accredited third-party laboratories within the United States.
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum threshold of 99% main-peak area purity. Molecular weight and sequence identity are validated using Electrospray Ionization Mass Spectrometry (ESI-MS). Furthermore, every batch is subjected to chromogenic LAL assays to ensure bacterial endotoxin levels remain strictly below <0.01 EU/μg, eliminating confounding inflammatory responses in biological assays. Research institutes requiring large-scale allocations can access bulk specifications through our wholesale laboratory portal.
What is the function of the DAC modification in CJC-1295 DAC 5mg?
The Drug Affinity Complex (DAC) is a reactive maleimide linker attached to the lysine residue of the peptide. It covalently binds to circulating serum albumin upon entry into biological media, extending the compound's functional half-life by protecting it from enzymatic cleavage by DPP-IV.
How does CJC-1295 DAC differ from CJC-1295 No DAC?
CJC-1295 DAC contains the maleimide complex allowing albumin binding and prolonged baseline GH elevation, whereas CJC-1295 No DAC lacks the complex, resulting in a short half-life (~30 minutes) that produces transient, pulse-like GHRH stimulation.
What diluent should be used to reconstitute CJC-1295 DAC 5mg?
Standard laboratory protocols utilize sterile bacteriostatic water (containing 0.9% benzyl alcohol) for multi-use analytical assays over 30 days, or sterile 0.9% sodium chloride solution for immediate single-assay applications.
What is the recommended storage temperature for lyophilized CJC-1295 DAC?
Lyophilized CJC-1295 DAC should be stored at -20°C in a dry, dark location. For long-term preservation beyond 12 months, storage at -80°C is recommended.
How does PX1 Research verify the purity of CJC-1295 DAC 5mg?
Each batch undergoes RP-HPLC analysis to confirm >99% purity, ESI-MS to verify exact molecular weight, and chromogenic LAL testing to ensure endotoxin limits remain below <0.01 EU/μg. A lot-specific Certificate of Analysis (COA) accompanies every order.
Can CJC-1295 DAC be combined with GHRPs in cellular research models?
Yes. In preclinical literature, GHRH agonists like CJC-1295 DAC are frequently evaluated alongside GHRP class compounds (such as Ipamorelin or GHRP-2) to study additive signaling effects across the GHRH-R and GHSR-1a receptors.
What molecular weight should be expected on mass spectrometry analysis?
The theoretical molecular weight of CJC-1295 with the Drug Affinity Complex (C88H139N27O22S) is approximately 3647.2 Da, which is verified via ESI-MS spectrum analysis on each Certificate of Analysis.
Is CJC-1295 DAC 5mg intended for human administration?
No. CJC-1295 DAC 5mg is supplied strictly as a research chemical for in vitro assays, laboratory models, and preclinical scientific investigation. It is not intended for human consumption, therapeutic use, or clinical application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.